Effect of a sibutramine/metformin combination on anti-Mffllerian hormone level, carbohydrate and lipid metabolisms in therapy for polycystic ovary syndrome in women with metabolic syndrome
- Autores: Andreeva E.N.1, Grigoryan O.R.2, Volevodz N.N.2, Melnichenko G.A.1
-
Afiliações:
- Endocrinology Research Center, Ministry of Health of Russia
- I.M. Sechenov First Moscow State Medical University
- Edição: Nº 4 (2016)
- Páginas: 112-119
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247687
- DOI: https://doi.org/10.18565/aig.2016.4.112-119
- ID: 247687
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
Palavras-chave
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
Elena Andreeva
Endocrinology Research Center, Ministry of Health of RussiaPh.D., Professor, Head of the Department of Endocrine Gynecology, with a group of screening and prevention of reproductive disorders
Olga Grigoryan
I.M. Sechenov First Moscow State Medical University
Email: iceberg1995@mail.ru
MD, main researcher, Endocrine Gynecology department with a group of screening and prevention of reproductive disorders
Natalia Volevodz
I.M. Sechenov First Moscow State Medical UniversityMD, professor, deputy director of preclinical diagnosis
Galina Melnichenko
Endocrinology Research Center, Ministry of Health of RussiaMD, professor, academician
Bibliografia
- Jonard S., DeWailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum. Reprod. Update. 2004; 10(2): 107-17.
- Eldar-Geva T., Margalioth E.J., Gai M., Ben-Chetrit A., Algur N., Zylber-Haran E. et al. Serum anti-Müllerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum. Reprod. 2005; 20(7): 1814-9.
- Laven J.S., Mulders A.G., Visser J.A., Themmen A.P., de Jong F.H., Fauser B.C. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J. Clin. Endocrinol. Metab. 2004; 89(1): 318-23.
- Pigny P., Merlen E., Robert Y., Cortet-Rudelli C., Decanter C., Jonard S., Dewailley D. Elevated serum level of anti-Müllerian hormone inpatients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicle arrest. J. Clin. Endocrinol. Metab. 2003; 88(12): 5957-62.
- Piouka A., Farmakiotis D., Katsikis I., Macut D., Gerou S., Panidis D. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am. J. Physiol. Endocrinol. Metab. 2009; 296(2): E238-43.
- Carlsen S.M., Vanky E., Fleming R. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum. Reprod. 2009; 24(7): 1732-8.
- La Marca A., Orvieto R., Giulini S., Jasonni V.M., Volpe A., De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil. Steril. 2004; 82(4): 970-2.
- Nardo L.G., Yates A.P., Roberts S.A., Pemberton P., Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum. Reprod. 2009; 24(11): 2917-23.
- Viollet B., Guigas B., Sanz Garcia N., Leclerc J., Foretz M., Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond). 2012; 122(6): 253-70.
- Tang T., Lord J.M., Norman R.J., Yasmin E., Baien A.H. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Database Syst. Rev. 2012; (5): CD003053.
- Du Q., Wang Y.J., Yang S., Wu B., Han P., Zhao Y. Y. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr. Med. Res. Opin. 2012; 28(5): 723-30.
- Fleming R., Harborne L., MacLaughlin D.T., Ling D., Norman J., Sattar N., Seifer D.B. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil. Steril. 2005; 83(1): 130-6.
- Piltonen T., Morin-Papunen L., Koivunen R., Perheentupa A., Ruokonen A., Tapanainen J.S. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum. Reprod. 2005; 20(7): 1820-6.
- The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004; 19(1): 41-7.
- Coutts J.R., Adam A.H., Fleming R. The deficient luteal phase may represent an anovulatory cycle. Clin. Endocrinol. (Oxf). 1982; 17(4): 389-94.
- Romualdi D., De Cicco S., Tagliaferri V., Proto C., Lanzone A., Guido M. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2011; 96(5): E821-4.
- Tomova A., Deepinder F., Robeva R., Kirilov G., Mechandjiev Z., Kumanov P. Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. Horm. Metab. Res. 2011; 43(10): 723-7.
- Thomson R.L., Buckley J.D., Moran L.J., Noakes M., Clifton P.M., Norman R.J., Brinkworth G.D. The effect of weight loss on anti-Müllerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum. Reprod. 2009; 24(8): 1976-81.
Arquivos suplementares
![](/img/style/loading.gif)